Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis

Critical Reviews in Oncology/Hematology

Volumn 92, Issue 2, 2014, Pages 71-82

  Qi, Wei Xiang ^a   Shen, Zan ^a   Tang, Li Na ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Angiogenesis inhibitors; Arterial thromboembolic events; Meta analysis; VEGFR TKIs

Indexed keywords

AXITINIB; BRIVANIB; CEDIRANIB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB; PROTEIN KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ARTERIAL THROMBOEMBOLISM; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CAUSAL ATTRIBUTION; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SAMPLE SIZE; SENSITIVITY ANALYSIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; NEOPLASMS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; THROMBOEMBOLISM;

ARTERIAL OCCLUSIVE DISEASES; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THROMBOEMBOLISM;

EID: 84908325508     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.04.004     Document Type: Review

References (65)

1. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972, 175:409-416.
2. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
3. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
4. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
5. Kulke M.H., Lenz H.J., Meropol N.J., Posey J., Ryan D.P., Picus J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26:3403-3410.
6. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
7. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
8. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
9. van der Graaf W.T., Blay J.Y., Chawla S.P., Kim D.W., Bui-Nguyen B., Casali P.G., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379:1879-1886.
10. Wells SA.Jr., Robinson B.G., Gagel R.F., Dralle H., Fagin J.A., Santoro M., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012, 30:134-141.
11. Motzer R.J., Escudier B., Tomczak P., Hutson T.E., Michaelson M.D., Negrier S., et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013, 14:552-562.
12. Rini B.I., Escudier B., Tomczak P., Kaprin A., Szczylik C., Hutson T.E., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
13. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer. Oncology (Williston Park) 2012, 26:896.
14. Qi W.X., Shen Z., Lin F., Sun Y.J., Min D.L., Tang L.N., et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol 2013, 75:919-930.
15. Qi W.X., Lin F., Sun Y.J., Tang L.N., He A.N., Yao Y., et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol 2013, 71:431-439.
16. Qi W.X., He A.N., Shen Z., Yao Y. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 2013, 76:348-357.
17. Wu S., Chen J.J., Kudelka A., Lu J., Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008, 9:117-123.
18. An M.M., Zou Z., Shen H., Liu P., Chen M.L., Cao Y.B., et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010, 66:813-821.
19. Zhu X., Stergiopoulos K., Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009, 48:9-17.
20. Qi W.X., Shen Z., Tang L.N., Yao Y. Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis. Clin Drug Investig 2014, 34:231-240.
21. Balagula Y., Wu S., Su X., Feldman D.R., Lacouture M.E. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2011.
22. Fischer A., Wu S., Ho A.L., Lacouture M.E. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2013.
23. Belum V.R., Wu S., Lacouture M.E. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs 2013.
24. Balagula Y., Wu S., Su X., Feldman D.R., Lacouture M.E. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2012, 30:1773-1781.
25. Chu D., Lacouture M.E., Weiner E., Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 2009, 7:11-19.
26. Qi W.X., Tang L.N., Sun Y.J., He A.N., Lin F., Shen Z., et al. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials. Ann Oncol 2013, 24:2943-2952.
27. Hapani S., Sher A., Chu D., Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010, 79:27-38.
28. Je Y., Schutz F.A., Choueiri T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009, 10:967-974.
29. Qi W.X., Sun Y.J., Tang L.N., Shen Z., Yao Y. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2014, 89:394-403.
30. Hapani S., Chu D., Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009, 10:559-568.
31. Ranpura V., Hapani S., Chuang J., Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010, 49:287-297.
32. Scappaticci F.A., Skillings J.R., Holden S.N., Gerber H.P., Miller K., Kabbinavar F., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99:1232-1239.
33. Schutz F.A., Je Y., Azzi G.R., Nguyen P.L., Choueiri T.K. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011, 22:1404-1412.
34. Choueiri T.K., Schutz F.A., Je Y., Rosenberg J.E., Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010, 28:2280-2285.
35. Motzer R.J., Hutson T.E., Cella D., Reeves J., Hawkins R., Guo J., et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013, 369:722-731.
36. Llovet J.M., Decaens T., Raoul J.L., Boucher E., Kudo M., Chang C., et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013.
37. Hyams D.M., Chan A., de Oliveira C., Snyder R., Vinholes J., Audeh M.W., et al. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized phase II study. Invest New Drugs 2013, 31:1345-1354.
38. Hutson T.E., Lesovoy V., Al-Shukri S., Stus V.P., Lipatov O.N., Bair A.H., et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013, 14:1287-1294.
39. Natale R.B., Thongprasert S., Greco F.A., Thomas M., Tsai C.M., Sunpaweravong P., et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:1059-1066.
40. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009, 62:1006-1012.
41. NCI, Cancer Therapy Evaluation Program. CTC v 2.0 and common terminology criteria for adverse events criteria V3.0 (CTCAE), http://ctepcancergov/protocolDevelopment/electronic_applications/ctchtm> [assessed 27.01 13].
42. Sweeting M.J., Sutton A.J., Lambert P.C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004, 23:1351-1375.
43. Zintzaras E., Ioannidis J.P. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005, 28:123-137.
44. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Staehler M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
45. Johnson P.J., Qin S., Park J.W., Poon R.T., Raoul J.L., Philip P.A., et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013, 31:3517-3524.
46. Abou-Alfa G.K., Johnson P., Knox J.J., Capanu M., Davidenko I., Lacava J., et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010, 304:2154-2160.
47. Goncalves A., Gilabert M., Francois E., Dahan L., Perrier H., Lamy R., et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012, 23:2799-2805.
48. Kindler H.L., Ioka T., Richel D.J., Bennouna J., Letourneau R., Okusaka T., et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011, 12:256-262.
49. Spano J.P., Chodkiewicz C., Maurel J., Wong R., Wasan H., Barone C., et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008, 371:2101-2108.
50. Groen H.J., Socinski M.A., Grossi F., Juhasz E., Gridelli C., Baas P., et al. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Ann Oncol 2013.
51. Scagliotti G., Novello S., von Pawel J., Reck M., Pereira J.R., Thomas M., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:1835-1842.
52. Gradishar W.J., Kaklamani V., Sahoo T.P., Lokanatha D., Raina V., Bondarde S., et al. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer 2013, 49:312-322.
53. Serve H., Krug U., Wagner R., Sauerland M.C., Heinecke A., Brunnberg U., et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013, 31:3110-3118.
54. Carrato A., Swieboda-Sadlej A., Staszewska-Skurczynska M., Lim R., Roman L., Shparyk Y., et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol 2013.
55. Ay C., Dunkler D., Marosi C., Chiriac A.L., Vormittag R., Simanek R., et al. Prediction of venous thromboembolism in cancer patients. Blood 2010, 116:5377-5382.
56. Seng S., Liu Z., Chiu S.K., Proverbs-Singh T., Sonpavde G., Choueiri T.K., et al. Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis. J Clin Oncol 2012.
57. Minor D.R. Risk of arterial thrombosis not increased by sorafenib or sunitinib. J Clin Oncol 2010, 28:e619. author reply e20.
58. Hurwitz H.I., Saltz L.B., Van Cutsem E., Cassidy J., Wiedemann J., Sirzen F., et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011, 29:1757-1764.
59. Nalluri S.R., Chu D., Keresztes R., Zhu X., Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008, 300:2277-2285.
60. Minor D.R. Risk of venous thromboembolism with bevacizumab in cancer patients. JAMA 2009, 301:1434. author reply 5-6.
61. Sonpavde G., Je Y., Schutz F., Galsky M.D., Paluri R., Rosenberg J.E., et al. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 2013, 87:80-89.
62. Qi W.X., Min D.L., Shen Z., Sun Y.J., Lin F., Tang L.N., et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer 2013, 132:2967-2974.
63. Barni S., Labianca R., Agnelli G., Bonizzoni E., Verso M., Mandala M., et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 2011, 9:179.
64. Petrelli F., Cabiddu M., Borgonovo K., Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 2012, 23:1672-1679.
65. Steingart R.M., Bakris G.L., Chen H.X., Chen M.H., Force T., Ivy S.P., et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J 2012, 163:156-163.